Estradiol

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Estradiol
    1. Pharmacist Assessment Report
    2. Estradiol: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Estradiol: Known uses and market status in Australia

Summary

The TxGNN model (score ≥ 0.99) produced candidates for Estradiol, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use found among the candidates is a knowledge graph relation, not an approved indication.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 1
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (3 of 3 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 3 (valid: 3)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
acne (disease)

Australia Market Information

Licence Product Dosage form Status
10203B Vagifem Low Pessary (modified release) 10 micrograms Valid
13932G Estalis sequi 50/140 Pack containing 4 transdermal patches 78 Valid
10146B Femoston 1/10 Pack containing 14 tablets estradiol 1 m Valid

Safety Considerations

Contraindications flagged in the knowledge graph. These are drug-disease contraindication links from the TxGNN knowledge graph, not label text. They should be verified against the Product Information (PI):

  • Cardiovascular and metabolic: hypertension, congestive heart failure, diabetes mellitus, hyperglycaemia
  • Hepatic, biliary and renal: liver failure, liver disease, gallbladder disease, kidney disease
  • Neurological and psychiatric: epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder
  • Endocrine: hypothyroidism (including myxedema and congenital hypothyroidism), adrenocortical insufficiency (Addison disease), humoral hypercalcaemia of malignancy
  • Other: porphyria, systemic lupus erythematosus, asthma, osteoporosis (listed in the graph, although osteoporosis is also an original indication, so this link should be treated with caution)

Drug interactions. The interaction screen returned 100 records; the first 20 are summarised here. Most are of moderate severity:

  • Antidiabetic agents: acarbose, alogliptin, albiglutide, metformin, pioglitazone, acetohexamide, chlorpropamide, canagliflozin and dapagliflozin
  • Corticosteroids: hydrocortisone, betamethasone, budesonide and dexamethasone
  • Others: amoxicillin, aprepitant, clarithromycin, clotrimazole, chenodeoxycholic acid and topical calcitriol (moderate); cimetidine (minor)

Please refer to the TGA-approved Product Information (PI) for full warnings, contraindications and interaction management.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.